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Oral antibiotic prescribing in the community setting is commonplace with ongoing efforts to 
optimize this practice. There are several concerns that relate to the practice and include antibiotic 
cost, development of bacterial resistance to these agents, and associated adverse drug events 
(ADR). We therefore performed an analysis of ADR associated with oral antibiotic prescriptions in 
community care (non-hospital) settings in England with the goal of determining both ADR 
reporting rates and severity due to oral antibiotics. 
Methods   
Data for all oral antibiotic use in the primary care settings in England and the National Yellow Card 
Interactive Drug Analysis Profile were both abstracted for 2010 through 2017.  
Results 
 Overall, there were 320,599,292 prescriptions issued for oral antibiotics during the eight-year 
survey. Although the overall ADR rate was relatively low, 58/1,000,000, the reported serious 
(63.6%) and fatal (1.21%) rates were striking.  
Conclusions 
Continued monitoring of ADR rates due to oral antibiotic prescribing in the community setting is 
warranted, considering the prevalence of serious/fatal reports identified during the eight-year 
study period in the Yellow Card profile. These data should be useful in developing strategies in 
securing optimal prescribing practices.  
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INTRODUCTION 
Prescribing oral antibiotics in the community (non-hospital) care setting may appear simple, but 
multiple factors are operative in defining the risk:benefit ratio of whether an antibiotic should be 
given to an individual patient.  This approach is even more difficult in the primary care setting 
where diagnostic laboratory screening is not available or if performed, results often delayed. 
Among these factors, adverse drug reactions (ADR) associated with oral antibiotic prescribing have 
to be considered in this decision-making to optimally manage a patient [1].  
In the present investigation, an analysis of prescription cost data for oral antibiotic 
prescribing in community settings across England was conducted.  Our aim was to characterize and 
quantify the rate of reported adverse drug reactions (ADR) to these drugs.   
METHODS 
The Prescription Cost Analysis data held by NHS Digital (https://digital.nhs.uk/data-and-
information/publications/statistical/prescription-cost-analysis) were abstracted to detect all oral 
antibiotics prescribed in the ambulatory care setting in England for 2010-2017.  Prescriptions were 
submitted by physicians, nurse practitioners, and other health care providers, including dentists.   
National Yellow Card Interactive Drug Analysis Profile data from the Medicines and 
Healthcare Products Regulatory Agency (MHRA) (http://yellowcard.mhra.gov.uk/iDAP/)  were 
interrogated and data extracted for all oral antibiotics or where the route of administration was not 
stated (reactions to drugs administered parenterally, topically or by other routes were excluded) to 
define  the ╉reported╊ ADR rate/million prescriptions calculated for the study period.  The Yellow 
Card system provides an opportunity for patients and healthcare professionals to report ADRs to 
the MHRA.  Reporting can be via either online submission or paper form mail-in, which is postage 
free.  This system has been in place for over 50 years and has been crucial for identifying ADRs, 
particularly those detected in the post-approval period. The Yellow Card data were previously used 
to examine the ADR rates of fluoroquinolones in the same population and ADR rates of oral 
antibiotics that were prescribed by dentists [2,3]. 
Because all data reported herein is anonymous, ethics approval was not required. 
 
RESULTS 
There were 320,599,292 prescriptions for oral antibiotics issued in the ambulatory care (non-
hospital) setting in England during the eight years (2010-2017) of the study period. The overall 
reported ADR rate was 57.9/1,000,000 prescriptions with 63.6% of reactions classified as serious 
and 1.21% of them as fatal (Table 1).    
The beta-lactam antibiotics, which included both penicillins and cephalosporins, widely 
varied in ADR rates (Table 1). For example, despite the relatively low use of ampicillin in the 
community setting, the overall reported rate of ADRs due to this agent was striking (683/1,000,000 
prescriptions) with 437/1,000,000 classified as severe, 27/1,000,000 as fatal, and 219/1,000,000 
as non-serious. In contrast, the overall reported ADR rates for amoxicillin, flucloxacillin, 
phenoxymethylpenicillin, and co-amoxiclave were much lower: 21.5/1,000,000 prescriptions, 
44/1,000,000 prescriptions, 137/1,000,000 prescriptions, and 71/1,000,000 prescriptions, 
respectively. Amoxicillin had the lowest ADR rate of all individual antibiotics examined and 
cephalosporins, as a class, had the lowest reported ADR rate (27.4/1,000,000 prescriptions) of all 
classes of antibiotics examined (Table 1).  
The reported ADR rates for some of the non-beta-lactam antibiotics were also high (Table 
1). This included the fluoroquinolones (250/1,000,000 prescriptions), clindamycin (337/1,000,000 
prescriptions), co-trimoxazole ゅぬぱぱ【な┸どどど┸どどど prescriptionsょ┸ and ╉other sulfonamides╊ 
(1,614/1,000,000 prescriptions). The fatal ADR rate for co-trimoxazole (21.2/1,000,000 
prescriptions) was second only to that (27.3/1,000,000 prescriptions) of ampicillin (Table 1). Of 
note, the overall and fatal reported ADR rates for trimethoprim alone were much lower 
(62/1,000,000 prescriptions and 0.6/1,000,000 prescriptions, respectively) ‒ close to the average 
for all antibiotics studied.   
DISCUSSION 
Our country-wide investigation focused on reported ADR related to oral antibiotic prescribing in 
the community care (non-hospital) setting in England. The Yellow Card reporting system, which has 
included data from 1964 to present, enabled us to conduct this investigation.  
The ampicillin reported ADR rates for serious and fatal events are striking in the current 
study.  Certainly, penicillins have been recognized as more likely causes of ADRs, some of which are 
potentially life-threatening [4].  While it is difficult to explain the differences in these rates between 
ampicillin and amoxicillin and co-amoxiclave, the extremely low prescription rate for ampicillin 
with only a total of 25 ADRs reported for the three categories of non-serious, serious and fatal 
events over eight years could have exaggerated ADR rate results. 
 Clindamycin has a strong association with risk of C. difficile infection as compared to that for 
many other classes of antibiotics.  In fact, in a recent meta-analysis, the odds ratio of developing C. 
difficile infection after clindamycin administration was 16.8 as compared to no antibiotic exposure, 
which was the highest of all classes of antibiotics examined [5].  It is therefore not surprising that 
clindamycin had such high rates of overall and fatal reported ADRs. 
As expected, the reported ADR rate for co-trimoxazole was much higher (~6-fold) than that for trimethoprim and included a high rate of fatal ADRs┹ the rate for the ╉other╊ sulfonamides was 
extremely high, but the scant number of prescriptions issued for these drugs over the study period 
makes it difficult to make conclusions about severity of reactions. 
The findings regarding macrolide/azalide use are not surprising (Table 1).  The well-
recognized gastrointestinal upset associated with erythromycin likely contributed to its ADR rate 
(47.2/1,000,000 prescriptions) [6]. The higher reported ADR rate (99/1,000,000 prescriptions) 
observed for clarithromycin, however, is difficult to explain, although it is tempting to speculate 
that because clarithromycin is a more recently available macrolide as compared to erythromycin, a 
Yellow Card report is more likely to be submitted for clarithromycin. 
 
Limitations 
Dependence on passive reporting in the Yellow Card reporting system method for characterizing 
the rate and types of reported ADRs was a major limitation which prevented the ability to calculate 
a true incidence rate of ADRs and may encourage reporting, and therefore overestimation, of more 
severe reactions and reactions occurring with newer agents.. Nevertheless, the results of this 
investigation are consistent with our current characterization of ADR associated with the oral 
antibiotics prescribed in the community setting. 
 
Conclusions 
The Yellow Card profile data have been collected for over five decades in England and provides 
helpful information to clinicians regarding ADR rates for oral antibiotics commonly prescribed in 
the community setting. The current investigation provides an update on ADR rates and their 
severity for both beta-lactam and non-beta-lactam antibiotics which may be helpful in designing an 
optimal oral antibiotic treatment regimen for an individual patient. 
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Table 1.  Adverse drug reaction data for oral antibiotic prescribing Ȃ England 2010-2017. 
  No of Adverse Reactions 
(2010-17) 
Adverse Reactions/Million Rx 
(2010-17) 
 
No of Rx 
2010-17 
Non-
Serious Serious Fatal Total 
Non-
Serious Serious Fatal Total 
Amoxicillin 101,663,837 956 1,214 14 2,184 9.4 11.9 0.1 21.5 
Co-Amoxiclave 16,343,274 330 809 25 1,164 20.2 49.5 1.5 71.2 
Ampicillin 36,590 8 16 1 25 218.6 437.3 27.3 683.2 
Flucloxacillin 33,392,162 502 957 10 1,469 15.0 28.7 0.3 44.0 
Phenoxymethylpenicillin 19,424,189 1,457 1,198 7 2,662 75.0 61.7 0.4 137.0 
Cephalosporins 10,731,391 97 192 5 294 9.0 17.9 0.5 27.4 
Tetracyclines 32,776,834 550 1,068 28 1,646 16.8 32.6 0.9 50.2 
Azithromycin 3,969,992 48 182 3 233 12.1 45.8 0.8 58.7 
Clarithromycin 17,398,169 543 1,140 22 1,705 31.2 65.5 1.3 98.0 
Erythromycin 16,065,288 318 429 11 758 19.8 26.7 0.7 47.2 
Clindamycin 681,841 69 159 2 230 101.2 233.2 2.9 337.3 
Co-Trimoxazole 902,502 82 249 19 350 90.9 275.9 21.1 387.8 
Trimethoprim 29,051,925 621 1164 17 1,802 21.4 40.1 0.6 62.0 
Other Sulfonamides 7,437 2 10 0 12 268.9 1,344.6 0.0 1,613.6 
Metronidazole 14,169,420 262 729 10 1,001 18.5 51.4 0.7 70.6 
Fluoroquinolones 6,411,315 251 1,314 40 1,605 39.1 205.0 6.2 250.3 
Methenamine 214,626 4 9 0 13 18.6 41.9 0 60.6 
Nitrofurantoin 17,358,500 428 947 23 1,398 24.7 54.6 1.3 80.5 















Aminoglycosides were excluded from this investigation since their oral absorption is minimal to 
none and was only 0.002% of overall oral antibiotic prescribing.  Similarly, fosfomycin was not 
included due to the limited use of the drug.  Linezolid and tidezolid were not included for analysis 
since these agents are only prescribed by secondary care.  A summary of the fluoroquinolone data 
will be included in the current investigation for the overall analysis of oral antibiotic use, although 
further details regarding oral fluoroquinolone use will not be included herein as they were the 
focus of a prior publication [2].   Oral antibiotics (isoniazid, rifampin, ethambutol, para-
aminosalicylic acid, pyrazinamide, clofazimine, bedaquiline, rifabutin, rifapentine, dapsone, 
ethionamide, cycloserine, prothionamide, and delamanid) used primarily to treat mycobacterial 
infections were excluded from the analysis.   
 
